VALENCIA, Calif.--(BUSINESS WIRE)--MannKind Corporation (Nasdaq: MNKD) today announced that the company will supply its novel, ultra rapid acting insulin AFREZZATM (insulin human [rDNA origin]) for use in a study being conducted by the Juvenile Diabetes Research Foundation (JDRF) as part of its Artificial Pancreas Project. The planned two-year study in patients with type 1 diabetes will leverage the unique rapid action of AFREZZA for use in a closed-loop blood sugar monitoring and insulin delivery system, termed the “artificial pancreas” by the JDRF. The study will be managed in conjunction with the Sansum Diabetes Research Institute and the University of California, Santa Barbara.
